The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis

The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Mona P., Abi Khalil, Charbel, Refaat, Marwan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/
https://www.ncbi.nlm.nih.gov/pubmed/29270438
http://dx.doi.org/10.1155/2017/9257930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/
https://www.ncbi.nlm.nih.gov/pubmed/29270438
http://dx.doi.org/10.1155/2017/9257930

Ejemplares similares